Trevi Therapeutics Inc

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Trevi Therapeutics reports transformative year with strong financial position

Trevi Therapeutics' strong performance in 2022, backed by positive trial results and financial stability, sets the stage for continued growth.
While facing challenges such as potential delays and increased expenses, Trevi's strategic planning and diverse opportunities position the company for success.
By leveraging its strengths in clinical development and upcoming data releases, Trevi aims to build scientific evidence and attract potential partners.
Overall, Trevi's focus on advancing its pipeline and showcasing trial results highlights its commitment to addressing unmet medical needs.

Trevi Therapeutics advances Haduvio trials, navigates regulatory challenges for growth

Trevi Therapeutics showcased progress in Haduvio's clinical development and financial stability despite a net loss.
The company faces challenges in dosing strategies, patent coverage, and regulatory hurdles but is poised for growth through strategic initiatives.

Trevi Therapeutics advances Haduvio in chronic cough, overcomes financial hurdles

Trevi Therapeutics is progressing with Haduvio's development in chronic cough indications
Financially, the company is managing its resources prudently and eliminating debt
Challenges persist with study delays due to supply shortages, but opportunities for growth are evident

Trevi Therapeutics advances Haduvio trials amidst financial stability

Trevi Therapeutics' financials show resilience with a focus on clinical advancements.
Challenges in trial planning and FDA outcomes require strategic navigation.
Opportunities for growth lie in upcoming trials and conference participation.
Overall, Trevi Therapeutics is positioned for continued progress and innovation.

Trevi Therapeutics advances novel cough treatments amidst financial challenges

Trevi Therapeutics is advancing innovative treatments for refractory chronic cough. Despite financial challenges, the company's strong cash position and ongoing clinical trials position it well for future growth.

Trevi Therapeutics reports Q1 loss, progresses in clinical trials

Trevi Therapeutics faces challenges with timelines for top line data in ongoing trials but holds promise in clinical development.
The company's financial performance reflects increased R&D expenses but maintains a strong cash position for future growth.

Trevi Therapeutics reports Q2 loss, advances in key trials

Trevi Therapeutics' Q2 2024 performance reflects ongoing investment in research with a net loss of $12.4 million and R&D expenses at $10 million.
Management's strategic focus on IPF and RCC trials, along with new leadership appointments and study initiations, underpin the company's commitment to therapeutic advancements.
While facing challenges like enrollment imbalances and financial pressures, Trevi Therapeutics remains poised for growth with upcoming data readouts and a strong research pipeline.

Trevi Therapeutics reports Q3 loss, eyes upcoming milestones and trials

Trevi Therapeutics is navigating increased R&D expenses, with a strong cash position and clear focus on upcoming data milestones. Analyst inquiries and ongoing trials present challenges, while opportunities lie in defining patient populations and regulatory decisions post-NDA submission.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW HAVEN, Conn., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will present a Company overview, as well as host virtual investor meetings, at the 2020 H.C. Wainwright Global Investment Conference on September 16, 2020:

Trevi Therapeutics to Present at H.C. Wainwright Global Investment Conference

Trevi Therapeutics, Inc. (TRVI) CEO Jennifer Good on Q2 2020 Results - Earnings Call Transcript

Announced Positive Outcome of Sample Size Re-Estimation Analysis for PRISM Trial

Trevi Therapeutics Announces Second Quarter 2020 Financial Results and Business Update

NEW HAVEN, Conn., Aug.  05, 2020  (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will participate in a virtual fireside chat, as well as host virtual investor meetings, at the  2020 BTIG Biotechnology Conference  on August 10, 2020:

Trevi Therapeutics to Present at BTIG Virtual Biotechnology Conference

Independent Data Monitoring Committee Recommends Continuation of PRISM Trial with Expansion to 360 Subjects per the Adaptive Design

Trevi Therapeutics Announces Positive Outcome of the Sample Size Re-Estimation Analysis in PRISM Trial for Severe Pruritus in Patients With Prurigo Nodularis

Seasoned biopharmaceutical executive with over 20 years of executive leadership and corporate development experience Seasoned biopharmaceutical executive with over 20 years of executive leadership and corporate development experience

Trevi Therapeutics Announces Election of Dominick C. Colangelo to  Board of Directors

NEW HAVEN, Conn., June  17, 2020  (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will present via a virtual fireside chat, as well as host virtual investor meetings, at the 2020 BMO Capital Markets Prescriptions for Success Healthcare Conference on June 23, 2020:

Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Virtual Conference

Carter Bankshares

Analysts on Wall Street recommend buying shares of Trevi Therapeutics Inc (NASDAQ:TRVI) and Carter Bank & Trust (NASDAQ:CARE), even though their share prices have lost more than 59% over the past 52 weeks through May 29.

Analysts Recommend Catching These 2 Falling Knives.

Seasoned biopharmaceutical executive with over 30 years of drug development experience Seasoned biopharmaceutical executive with over 30 years of drug development experience

Trevi Therapeutics Announces Election of James V. Cassella, Ph.D.

Trevi Therapeutics: A Promising Pruritus Player In 2020

Trevi Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

Trevi Therapeutics Sees Hammer Chart Pattern: Time to Buy?

NEW HAVEN, Conn., Sept.  05, 2019  (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that Jennifer L. Good, President and Chief Executive Officer of Trevi Therapeutics, will participate in a panel discussion, as well as host investor meetings, at the BTIG Pain / Pruritus Management Forum being held on Wednesday, September 11, 2019 in New York City.

Trevi Therapeutics to Participate in Panel Discussion at BTIG Pain / Pruritus Management Forum

Trevi Therapeutics Inc (NASDAQ: TRVI) priced its 5.5 million share IPO at $10 May 7, and shares have been mostly trading at a discount since then.

News for Trevi Therapeutics Inc Stock (TRVI)